Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.24M Sell
17,426
-140
-0.8% -$16.4K 0.57% 52
2026
Q1
$2.11M Buy
17,566
+5,280
+43% +$610K 0.59% 50
2025
Q4
$1.29M Buy
12,286
+2,460
+25% +$231K 0.35% 62
2025
Q3
$825K Sell
9,826
-5,410
-36% -$446K 0.23% 72
2025
Q2
$1.21M Sell
15,236
-1,511
-9% -$120K 0.37% 65
2025
Q1
$1.5M Sell
16,747
-2,187
-12% -$204K 0.51% 62
2024
Q4
$1.88M Sell
18,934
-10,949
-37% -$1.13M 0.63% 52
2024
Q3
$3.39M Buy
29,883
+70
+0.2% +$8.32K 1.09% 30
2024
Q2
$3.69M Buy
29,813
+391
+1% +$50.4K 1.32% 23
2024
Q1
$3.88M Buy
29,422
+840
+3% +$104K 1.35% 20
2023
Q4
$3.12M Buy
28,582
+115
+0.4% +$11.9K 1.2% 26
2023
Q3
$2.93M Buy
28,467
+1,557
+6% +$168K 1.26% 23
2023
Q2
$3.11M Buy
26,910
+8,196
+44% +$931K 1.29% 24
2023
Q1
$1.99M Sell
18,714
-499
-3% -$53.9K 0.89% 40
2022
Q4
$2.13M Hold
19,213
1.05% 30
2022
Q3
$1.66M Buy
19,213
+614
+3% +$54.8K 1.02% 34
2022
Q2
$1.7M Buy
18,599
+5,030
+37% +$446K 1.01% 33
2022
Q1
$1.13M Buy
13,569
+7,259
+115% +$572K 0.64% 51
2021
Q4
$485K Buy
+6,310
New +$503K 0.39% 80

Other funds holding MRK

Stone Summit Wealth's MRK Position: Q2 2026 in Review

Stone Summit Wealth reduced its Merck (MRK) stake by 0.8% in Q2 2026, selling an estimated $16.4K and leaving 17,426 shares worth $2.24M. The position accounts for 0.57% of the portfolio, ranked #52.

Stone Summit Wealth first reported a position in MRK in Q4 2021 and has held it in 19 quarters since. The position peaked at $3.88M in Q1 2024. 1,867 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Stone Summit Wealth held 17,426 shares of Merck worth $2.24M as of Q2 2026.
  • Stone Summit Wealth sold 140 Merck shares in Q2 2026, an estimated $16.4K.
  • Merck made up 0.57% of Stone Summit Wealth's portfolio in Q2 2026, its #52 holding.
  • Stone Summit Wealth first reported a position in Merck in Q4 2021 and has held it in 19 quarters since.
  • Stone Summit Wealth's Merck position peaked at $3.88M in Q1 2024.
  • 1,867 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Stone Summit Wealth's 13F filing for Q2 2026, filed 23 Jul 2026.